Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Heterologous prime-boost immunization with DNA and various recombinant poxviruses encoding malaria antigens is capable of inducing strong cell-mediated immune responses and partial protection in human sporozoite challenges. Here we report a series of trials assessing recombinant fowlpox virus and modified vaccinia virus Ankara encoding the Plasmodium falciparum circumsporozoite protein in various prime-boost combinations, doses, and application routes. For the first time, these vaccines were administered intramuscularly and at doses of up to 5 x 10(8) PFU. Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge.

Original publication

DOI

10.1128/IAI.74.5.2706-2716.2006

Type

Journal article

Journal

Infect Immun

Publication Date

05/2006

Volume

74

Pages

2706 - 2716

Keywords

Adult, Animals, Antibodies, Protozoan, Clinical Trials as Topic, Glycosylphosphatidylinositols, Humans, Immunization, Secondary, Interferon-gamma, Malaria Vaccines, Parasitemia, Plasmodium falciparum, Poxviridae, Protozoan Proteins, Vaccines, Synthetic, Vaccinia virus